We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-9.76%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$16.2B
AUM Growth
-$2.57B
Cap. Flow
+$150M
Cap. Flow %
0.93%
Top 10 Hldgs %
86.32%
Holding
116
New
17
Increased
25
Reduced
19
Closed
6

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$49.3M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$43.3M
3
KOD icon
Kodiak Sciences
KOD
+$31.6M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$27.5M
5
ALLK
Allakos
ALLK
+$27.1M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$60M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$48.2M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$10.4M
4
QURE icon
uniQure
QURE
+$9.23M
5
NXTC icon
NextCure
NXTC
+$8.45M

Sector Composition

Rank Sector Weight
1 Healthcare 98.58%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$5.78B 35.57%
50,060,240
+2,963
+0% +$328K
INCY icon
2
Incyte
INCY
$25.3B
$2.34B 14.42%
31,978,785
+1,912
+0% +$144K
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.46B
$1.77B 10.9%
41,904,586
+1,050,000
+3% +$43.3M
ONC
4
BeOne Medicines Ltd
ONC
$34.1B
$1.45B 8.93%
11,777,285
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$787M 4.84%
8,760,794
+502,726
+6% +$49.3M
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12B
$641M 3.95%
7,589,294
– –
KOD icon
7
Kodiak Sciences
KOD
$2.43B
$552M 3.4%
11,574,538
+527,249
+5% +$31.6M
ASND icon
8
Ascendis Pharma A/S
ASND
$16.7B
$382M 2.35%
3,390,270
– –
IGMS
9
DELISTED
IGM Biosciences
IGMS
$177M 1.09%
3,144,000
– –
AMRN
10
Amarin Corp
AMRN
$294M
$138M 0.85%
1,724,834
– –
ARGX icon
11
argenx
ARGX
$55.2B
$134M 0.83%
1,019,557
– –
NVTA
12
DELISTED
Invitae Corporation
NVTA
$124M 0.77%
9,100,615
+3,450
+0% +$63K
PRNB
13
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$116M 0.72%
1,955,413
+167,456
+9% +$9.76M
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$108M 0.67%
1,409,784
+102,564
+8% +$9.2M
NBIX icon
15
Neurocrine Biosciences
NBIX
$18.3B
$107M 0.66%
1,240,243
-14,000
-1% -$1.37M
EXAS
16
DELISTED
Exact Sciences
EXAS
$107M 0.66%
1,846,139
-739,652
-29% -$60M
RARX
17
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$101M 0.62%
2,093,839
– –
MDGL icon
18
Madrigal Pharmaceuticals
MDGL
$12.5B
$100M 0.62%
1,499,212
+329,934
+28% +$27.5M
MYOK
19
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$83.2M 0.51%
1,774,234
– –
HRTX icon
20
Heron Therapeutics
HRTX
$92.5M
$70.7M 0.44%
6,018,104
– –
CERS icon
21
Cerus
CERS
$579M
$63.8M 0.39%
13,713,195
+2,963,258
+28% +$13.4M
ZYME icon
22
Zymeworks
ZYME
$1.62B
$60.6M 0.37%
1,708,472
– –
TCDA
23
DELISTED
Tricida, Inc. Common Stock
TCDA
$58.7M 0.36%
2,666,015
+696,110
+35% +$22.3M
BCEL
24
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$58.5M 0.36%
3,532,760
– –
DBVT
25
DBV Technologies
DBVT
$795M
$57.3M 0.35%
1,461,426
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2020 Portfolio in Review

As of Q1 2020, Baker Bros. Advisors held 116 positions worth $16.2B, down 14% from $18.8B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q1 2020 filing shows 17 new, 25 increased, 19 reduced and 6 closed positions. Its largest new stake was Adaptimmune Therapeutics: 3,690,307 shares worth $10M. The largest sale was Exact Sciences, an estimated $60M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2020 buy was Adaptimmune Therapeutics: 3,690,307 shares worth $10M.
  • Baker Bros. Advisors added most to Alexion Pharmaceuticals in Q1 2020, an estimated $49.3M increase.
  • Baker Bros. Advisors's biggest Q1 2020 reduction was Exact Sciences, cutting an estimated $60M.
  • Baker Bros. Advisors fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $48.2M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $16.2B portfolio in Q1 2020.
  • Baker Bros. Advisors opened 17 new positions and closed 6 in Q1 2020.
  • Baker Bros. Advisors's portfolio value fell 14% quarter-over-quarter to $16.2B.

Based on Baker Bros. Advisors's 13F filing for Q1 2020, filed 15 May 2020.